组别n/例观察时间IL-18/(pg·mL−1) CRP/(mg·L−1) WBC/(×109·L−1) | |||||
对照 | 38 | 治疗前 | 19.20 ± 4.36 | 21.03 ± 6.59 | 10.17 ± 2.36 |
治疗后 | 14.81 ± 3.12* | 9.46 ± 2.18* | 7.90 ± 2.04* | ||
t |
| 6.343 | 7.455 | 5.459 | |
P |
| 0.014 | 0.011 | 0.025 | |
治疗 | 38 | 治疗前 | 19.64 ± 3.54 | 21.84 ± 6.20 | 10.83 ± 2.15 |
治疗后 | 12.06 ± 2.59*▲ | 7.35 ± 2.01*▲ | 6.24 ± 1.57*▲ | ||
t |
| 1.235 | 2.545 | 2.095 | |
P |
| 0.042 | 0.035 | 0.034 | |
t治疗前组间值 |
|
| 0.874 | 0.725 | 0.975 |
P治疗前组间值 |
|
| 0.142 | 0.252 | 0.098 |
t治疗后组间值 |
|
| 4.842 | 10.432 | 11.534 |
P治疗后组间值 |
|
| 0.015 | 0.011 | 0.008 |